BRCA2 and cancer: In addition, cancer cells were isolated from mice and then tested for sensitivity to chemotherapeutic agents, demonstrating that BRCA2-deficient pancreatic tumors exhibit increased sensitivity to cisplatin and PARP inhibitors [183].